Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer by Carina Ørts Christensen et al.
ORIGINAL ARTICLE
Change in bone mineral density during adjuvant chemotherapy
for early-stage breast cancer
Carina Ørts Christensen1,2 & Deirdre Cronin-Fenton3 & Trine Frøslev3 &
Anne Pernille Hermann2,4 & Marianne Ewertz1,2
Received: 14 March 2016 /Accepted: 25 April 2016 /Published online: 5 May 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Purpose Adjuvant chemotherapy has been associated with
loss of bone mineral density (BMD) either as a direct effect
or due to glucocorticoids used as supportive care medication.
A prospective cohort study was conducted to evaluate changes
in BMD from baseline to right after completion of chemother-
apy, i.e., 4 months.
Methods Dual-imaging X-ray absorptiometry (DXA) was
performed at baseline and after completing anthracycline-
and taxane-based chemotherapy to measure BMD in the
spine, hip, and forearm in early-stage breast cancer patients.
High-dose prednisolone was used at three weekly intervals to
reduce nausea and vomiting. Patients were advised a daily
calcium/vitamin D supplement. Linear regression was used
to assess mean percentage change in BMD and 95 % confi-
dence intervals (95 % CI) according to doses of prednisolone,
menopausal status, smoking, and BMI.
Results Eight patients were excluded: seven because of initia-
tion of bisphosphonate treatment due to osteoporosis at base-
line, and one had non-interpretable DXA. The final cohort in-
cluded 97 patients with a mean age of 53 years (range 34–72).
Mean cumulative prednisolone dose was 1308 mg (95 % CI
1255; 1362). BMD increased 1.36 % (95 % CI 0.7; 2.0,
p < 0.001) in the spine and 1.27 % (95 % CI 0.9; 1.7,
p < 0.001) in the hip. Forearm BMD did not change.
Postmenopausal women had increases in spine BMD of
2.35 % (95 % CI 1.1; 3.6, p<0.001) compared to premeno-
pausal women. The spine BMD of current smokers decreased
1.67 % (95 % CI −3.3; −0.1, p=0.04) compared to never/
former smokers.
Conclusions Adjuvant chemotherapy supplemented with
prednisolone was not associated with loss of BMD.
Postmenopausal women gained bone mass, whereas current
smokers lost bone mass.
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Background
Breast cancer is the most frequent malignant disease among
women worldwide with an estimated 1.67 million new cases
diagnosed in 2012 (25% of all cancers in women) and the fifth
most common cause of death from cancer (522,000 deaths)
[1]. Survival after breast cancer has improved substantially
over the past 30–40 years [2] which is likely to be explained
by earlier diagnosis via mammography screening and by
advances in cancer-directed treatment [3]. Today, more than
90% of patients with early-stage breast cancer are allocated to
adjuvant medical treatment with chemotherapy, anti-HER2-
treatment, and endocrine therapy depending on the biomarker
profile of the primary tumor [4]. Since more than 80 % of
breast cancer patients are expected to live for 10 years or
longer, it is increasingly important to focus on potential harm-
ful late-effects of the cancer treatment, such as osteoporosis.
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Osteoporosis is characterized by reduced bone mass, deteri-
oration of the bone micro-architecture, and an increased risk of
fragility fractures. It affects millions of people worldwide, with
the highest prevalence among postmenopausal women. The
gold standard for evaluating osteoporosis is measuring bone
mineral density (BMD) by dual energy X-ray absorptiometry
(DXA), which measures the bone in two dimensions [5].
There are several ways in which breast cancer chemother-
apy can increase the risk of osteoporosis but in general, the
evidence is sparse. It can induce premature menopause with
menopause occurring on average 10 years earlier than normal
[6]. We have identified a total of four studies, including 41 to
53 premenopausal breast cancer patients, who received
chemotherapy with CMF (cyclophosphamide, methotrexate,
fluorouracil) or anthracycline-cyclophosphamide regimens
(AC) with measurements of BMD at baseline and 6 months
later [7–10]. They demonstrated decreases in BMD in the
lumbar spine of 1–4 %. It has been suggested that the bone
loss may be associated with supportive care medication such
as corticosteroids which are the most common cause of
secondary osteoporosis with a 7–17-fold increased risk of
fractures with daily doses of 10 mg for 3 months [11].
However, women undergoing chemotherapy receive much
higher glucocorticoid doses albeit for short durations. Based
on 16 patients with Graves’ ophthalmopathy, increases in
BMD of 3 % were found for treatment with high-dose gluco-
corticoids given as intravenous pulse-therapy, whereas BMD
decreased 2.7 % in patients who received high-dose oral
glucocorticoids continuously [12].
We conducted a prospective cohort study to evaluate the
effect of adjuvant chemotherapy supplemented with high-
dose glucocorticoids (prednisolone) on BMD among patients
with early-stage breast cancer. We evaluated the combined
effect of chemotherapy and prednisolone in the spine, hip,




We recruited women aged 18 years or older diagnosed with
histologically verified early-stage breast cancer who
underwent surgery (mastectomy or lumpectomy) with axillary
node excision (sentinel node or axillary dissection). Patients
with inflammatory breast cancer, locally advanced or dissem-
inated breast cancer, or primarily unresectable breast carcino-
ma were excluded. Patients were also excluded if diagnosed
with any other malignancy within the past 5 years that
required chemotherapy, had a pre-existing diagnosis of osteo-
porosis, or currently received systemic treatment with
steroids. Women, who for various reasons, were deemed
incapable of participating in the study due to psychiatric
illness, difficulties understanding the Danish language, or
physically unable to lie still when the DXA scan was per-
formed were also excluded.
Patients were referred to the Department of Oncology,
Odense University Hospital (OUH), Denmark, for adjuvant
medical treatment from September 1, 2013 through August
31, 2014. They were offered a DXA scan at baseline before
their first cycle of chemotherapy, and a second DXA scan
approximately 3 weeks after their last cycle of chemotherapy.
To be included in the final analyses, patients had to complete
both DXA scans, receive at least five cycles of adjuvant
chemotherapy, and not start bisphosphonate treatment for
osteoporosis during chemotherapy.
Informed consent was obtained from all the participants.
This study was approved by the Danish Data Protection Board
(ID 2008-58-0035) and ethics committee in Region of
Southern Denmark (Project ID S-20130065).
Chemotherapy
In the majority of the patients, adjuvant chemotherapy
consisted of three cycles of epirubicin (90 mg/m2) and cyclo-
phosphamide (600 mg/m2) (EC) followed by three cycles of
docetaxel (100 mg/m2) intravenously on day one at three
weekly intervals, while some received two to six cycles of
EC or docetaxel. There were no statistically significant differ-
ences in baseline characteristics between these two patient
groups (data not shown). During EC chemotherapy, glucocor-
ticoids were given as anti-emetic prophylaxis with a typical
dose of 175 mg prednisolone for one cycle of EC, i.e., 525 mg
in total for three cycles. During one cycle of docetaxel,
patients received a standard dose of prednisolone 100 mg/
day for 3 days, i.e., 300 mg/cycle, in total 900 mg for three
cycles. Provided that patients did not need additional prednis-
olone beyond the amount given during chemotherapy, patients
received in total 1425 mg prednisolone over an 18-week treat-
ment period.
From March 2014, new guidelines were introduced at the
Department of Oncology, OUH, regarding anti-emetic treat-
ment in breast cancer patients. Thus, patients received 75 mg
prednisolone instead of 175 mg prednisolone at each cycle of
EC. This resulted in a reduction in the total prednisolone dose
to 1125 mg prednisolone over the 18-week treatment period
for the adjuvant regimen. All patients were advised to take a
daily supplement of calcium (800 mg) and vitamin D (20 μg)
while undergoing chemotherapy. No patients received
concomitant endocrine treatment with their chemotherapy.
Data sources
Baseline data were abstracted from the patient records on date
and type of surgery, co-morbidity, prior cancers, regular
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medication, menopause, tobacco consumption, adjuvant
cancer-directed treatments, number of treatment cycles, and
anti-emetic treatment with glucocorticoids. Data were ab-
stracted from the pathology report on tumor size, histological
type and grade, estrogen receptor (ER) status (% positivity),
human epidermal growth factor receptor 2 (HER-2) status,
and nodal status. Data were derived directly from the DXA
scanner at the Osteoporosis Clinic, Department of
Endocrinology, OUH, and included dates of baseline and
follow-up scans, height, weight, T- and Z-scores, area (g),
bone mineral content (cm2), and BMD (g/cm2) in the spine,
hip, and forearm.
Bone densitometry
BMD measurements of the lumbar spine (L1–L4), left hip,
and left forearm were obtained using Hologic Discovery
QDR, Scanner ID: 82245. All scans were performed by
specially trained personnel, and quality standards of the scan-
ner were tested daily with a BHologic Spine Phantom^ ID:
13520 with a median BMD value of 0.974 (0.9594–0.9887).
Coefficients of variation (CV) of the BMD measurements
were 1.025 and 0.875 % for the lumbar spine and hip,
respectively.
Osteoporosis was defined by the World Health
Organization (WHO) as a BMD below a certain value, i.e., a
T-score for BMD less than 2.5 standard deviations (SDs)
below the mean value expected for a young healthy female
adult either in the spine and/or the hip. The relative BMD
value, the Z-score, describes the number of SDs by which
the BMD in an individual differs from the mean value expect-
ed for age and sex [5]. Spine T- and Z-scores were calculated
with the Hologic manufacturer’s reference ranges, and for the
hip region, the National Health and Nutrition Examination
Survey (NHANES) III reference ranges were used [13].
Exposure variables
The cumulative dose of prednisolone was calculated as
follows: the total dose of prednisolone received during
chemotherapy was calculated as the sum of each prednisolone
dose administered during each cycle of chemotherapy. In case
of an allergic reaction to chemotherapy, the patient received
additional methylprednisolone in the acute phase. The dose of
methylprednisolone was converted to prednisolone equivalent
doses, i.e., multiplying the dose of methylprednisolone by the
conversion factor 1.25. The cumulative dose of prednisolone
also included any additional prednisolone administered to
patients in the 3-week periods between each cycle of chemo-
therapy. Women who at diagnosis had a menstrual period
within the last 12 months were categorized as premenopausal.
The others were categorized postmenopausal. Body mass
index (BMI) was calculated as weight in kilograms divided
by the square of the height in meters. BMI was categorized
according to World Health Organization (WHO) criteria as
normal (less than 25), overweight (25–30), or obese (30 or
more). Patients were categorized into two categories of
smoking: current or never/former smokers.
Statistical analyses
Baseline BMD at each of the three anatomic sites was checked
for normality by use of Shapiro-Wilks test and found to be
normally distributed. Percentage change in BMD was calcu-
lated as (BMD at follow-up−BMD at baseline) / BMD at
baseline×100 % in the spine, hip, and forearm, respectively.
Categorical data were described using frequencies and
percentages. Continuous data were described using means
± standard deviations. We used uni- and multivariate linear
regression to test the association between percentage change
in BMD of the spine, hip, and forearm by different factors
hypothesized to impact BMD either in a positive (e.g., BMI)
or negative (e.g., cumulative dose of prednisolone, menopaus-
al status, and smoking) direction. In the full model, we adjust-
ed for all the factors. We used linear regression to compute the
mean percentage change in BMD, and 95 % confidence inter-
vals (95 % CI) for the spine, hip, and forearm BMD. All
statistical analyses were carried out using STATA/IC 14.0.
Results
The study consort diagram is shown in Fig. 1. Among 168
potentially eligible breast cancer patients, 36 did not meet the
inclusion criteria. A further 21 patients with a mean age of 51
(range 31–73) years withdrew informed consent or had no
baseline DXA scan. One hundred and five out of 111 patients
(95 %) completed both the baseline and the second DXA scan
at completion of chemotherapy. The entire study population
had mean Z-scores of 0.3, 0.2, and 0.2 in the lumbar spine, hip
and forearm, respectively (Table 1). Ten patients (9 %) were
diagnosed with osteoporosis at baseline with a mean T-score
of −2.8 (95 % CI −3.1; −2.5) in the spine and −1.9 (95 % CI
−2.2; −1.7) in the hip. Seven patients with a mean age of 56
(range 35–65) years were excluded from further analyses due
to bisphosphonate treatment during chemotherapy, and one
patient due to an unreadable baseline DXA. For all character-
istics, these patients were similar to the other patients.
A total of 97 patients were included in the final analyses.
Their mean age was 53 (range 34–72) years, and 8 of the
patients were younger than 40 years. Most tumors (91 %)
were invasive ductal carcinomas, with 81 % estrogen receptor
positive, 17 % HER-2 positive, and 39 % lymph node posi-
tive. About 24 % of patients had a BMI above 30, and 18 %
were current smokers (Table 1). At baseline, no patients were
treated with systemic glucocorticoids but 13 % were using
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inhaled corticosteroids, nose sprays, crème, or suppositories
with corticosteroids either on a regular basis or as required.
Four patients had an allergic reaction related to docetaxel and
received additional methylprednisolone in the acute phase.
During chemotherapy, patients received a median total
cumulative prednisolone dose of 1325 mg with 90 % of
patients receiving at least 1125 mg (range 475–2046 mg).
Mean prednisolone dose was 1308 mg (95 % CI 1255;
1362). In uni- and multivariate analyses, no statistically
significant associations were found between cumulative dose
of prednisolone and percentage change in BMD at all three
anatomic sites.
At baseline, 55 % had a normal BMD, 42 % had
osteopenia, and 3 % were osteoporotic. Mean BMD at base-
line was 0.98 g/cm2 (95 % CI 0.96; 1.01) for the spine, 0.90 g/
cm2 (95 % CI 0.87; 0.92) for the hip, and 0.65 g/cm2 (95 % CI
0.64; 0.67) for the forearm. Mean time interval from baseline
to the second DXA scan was 4.4 (range 3.6–6.3) months.
Increases were observed in spine BMD of 1.36 % (95 % CI
0.7; 2.0, p<0.001) and hip BMD of 1.27 % (95 % CI 0.9; 1.7,
p<0.001) while forearmBMDdid not change (−0.19%, 95%
CI −0.7; 0.3, p=0.5) (Fig. 2).
Table 2 shows that no change in spine BMD was observed
in premenopausal women whereas there was a significant
increase of 2.42 % among postmenopausal women.
Adjusting for the effects of other variables in multivariate
analyses, the significant increase in spine BMD of 2.35 %
(95 % CI 1.1; 3.6, p<0.001) persisted in postmenopausal
women compared with premenopausal women. Among
current smokers BMD decreased 1.67 % (95 % CI −3.3;
−0.1, p=0.04) compared with never/former smokers. The
multivariate analyses did not reveal any significant association
between BMI and BMD. No significant associations were
detected between hip and forearm BMD and the investigated
characteristics (data not shown).
Discussion
The literature indicates that continuous use of glucocorticoids
is associated with loss of bone mass. However, contrary to
expectation, we observed no significant changes in BMD
associated with prednisolone dose. A bone loss of 10 % cor-
responds to a reduction of 1 SD, which is expected to increase
the risk of fractures by a factor two to three [14].
Glucocorticoids have shown to increase bone resorption and
decrease bone formation [15]. This effect seems to persist
throughout the duration of glucocorticoid treatment.
Moreover, continuous use of glucocorticoid therapy is associ-
ated with increased risk of fracture with increasing dose and
duration of treatment, particularly, within the first 3 to
6 months. A few months after cessation of the treatment, a
corresponding rapid decrease is seen in fracture risk [16].
Based on 191,752 patients from the UK General Practice
Database who were followed for 10 years, De Vries et al.
reported a strong association between continuous daily doses
of oral glucocorticoids (cumulative exposure >1 g of prednis-
olone) and risk of fracture, whereas patients who received
intermittent high-dose oral glucocorticoids were associated
with a substantial lower risk of fractures [17].
Patients in our study received a mean prednisolone dose of
1304 mg administered at intervals with chemotherapy. Since
no bone loss was observed, our data demonstrate that such a
chemotherapy regimen seems safe. This is reassuring because
glucocorticoids are essential in preventing chemotherapy-
induced nausea and vomiting [18]. We investigated a limited
period of 4 months. During this time, no fractures were report-
ed. However, we cannot rule out the possibility that patients,
due to exposure of glucocorticoids, may be at increased risk of
fractures, since other studies have reported increased fracture
risk caused by deterioration of bone quality, which is not
captured by BMD [19, 20].
Interestingly, we found increases in both spine and hip
BMD from baseline to completion of adjuvant chemotherapy.
In spine BMD, the increase was statistically significant among
postmenopausal women whereas current smokers had a sig-
nificant decrease compared to never/former smokers.
Animal studies have shown that cytotoxic agents such as
doxorubicin and methotrexate reduce bone formation by
reducing osteoblastic activity in rats [21, 22]. Four studies
reported changes in spine and hip BMD in breast cancer
patients during a 6-month period after start of chemotherapy
Fig. 1 Consort diagram of the study population
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[7–10]. Based on 41 to 53 premenopausal patients who
received CMF- or AC-based chemotherapy, decreases were
reported in BMD of 1–4 % in the spine and −0.7 to 2.6 % in
the hip. Cameron et al. reported on 41 premenopausal women
with decreases in BMD of 4 % in the spine and 2 % in the hip
[10]. Nine patients received chemotherapy with docetaxel. All
patients received glucocorticoids (dexamethasone) as anti-
emetic treatment. However, the dose and regimen of gluco-
corticoids was not stated. Nor was it mentioned whether the
patients received supplements of calcium and vitamin D.
In our study, the time interval between baseline and
follow-up DXA was 4.4 months, and patients represented
a mix of both pre- and postmenopausal women. Since our
finding is not in line with previous findings, we cannot rule
out that the rather short time of follow-up may be a possi-
ble explanation. However, our findings may be explained
by the calcium and vitamin D given in our study, which is
known to affect bone turnover rate in persons with low
calcium intake or low calcium absorption, e.g., postmeno-
pausal women [23].
Table 1 Characteristics of the
study population Patients in total N= 111 (%) Patients in final analyses N= 97 (%)
Age at diagnosis
50 32 (29) 30 (31)
50–59 53 (48) 47 (48)
≥60 26 (23) 20 (21)
Menopausal status
Premenopausal 45 (41) 43 (44)
Postmenopausal 66 (59) 54 (56)
Type of surgery
Lumpectomy 63 (57) 56 (58)
Mastectomy 48 (43) 41 (42)
Type of carcinoma
Ductal 101 (91) 88 (91)
Lobular 4 (4) 4 (4)
Others 6 (5) 5 (5)
Tumorsize
0–9 mm 6 (5) 4 (4)
10–19 mm 51 (46) 43 (44)
20+mm 54 (49) 50 (52)
Histological grade
Low (I) 15 (14) 11 (11)
Moderate (II) 36 (32) 30 (31)
High (III) 54 (49) 51 (53)
(Unknown) 6 (5) 5 (5)
Estrogen status
ER negative 0 % 19 (17) 18 (19)
ER poor 1–10 % 6 (5) 6 (6)
ER positive 10 % 86 (78) 73 (75)
HER2 status
HER2 negative 92 (83) 81 (83)
HER2 positive 19 (17) 16 (17)
Nodal status
Node negative 67 (60) 59 (61)
Node positive 44 (40) 38 (39)
Body mass index (kg/m2)
25 normal 43 (39) 38 (39)
25–30 overweight 38 (34) 36 (37)
30 obese 30 (27) 23 (24)
Smoking status
Never/former smokers 91 (82) 80 (82)
Current smokers 20 (18) 17 (18)
Baseline T-score
Spine −0.7 ± 1.3bc −0.5 ± 1.2b
Hip −0.5 ± 1.1a −0.4 ± 1.0a
Forearm −0.8 ± 1.0a −0.7 ± 1.0a
Baseline Z-score
Spine 0.3 ± 1.3ab 0.4 ± 1.2a
Hip 0.2 ± 1.1a 0.3 ± 1.1a
Forearm 0.2 ± 1.0a 0.3 ± 0.9a
aMean ± standard deviation (SD)
bN= 110 patients
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Physiologically, premenopausal women have a low bone
turnover compared to postmenopausal women who have a
higher bone turnover. Moreover, the spine has the largest bone
surface, and it consists primarily of cancellous bone. Thus, the
spine is the location where changes in bone turnover are first
seen [24]. This correlates well with our results detected in the
spine. Moreover, the significant increases in spine BMD seen
in older women are compatible with normal physiology of the
bones. When women enter menopause, they undergo two
phases of bone loss. An initial accelerated phase of predomi-
nantly cancellous bone loss that declines rapidly over 4–8 years
which subsequently merges with a slow phase that continues
indefinitely [25]. The majority of premenopausal women who
receive chemotherapy experience chemotherapy-induced ovar-
ian failure (CIOF) with rapid decreases in estrogen levels and a
shift in bone turnover from a low to a high state [26]. This is
seen as a decrease in BMD measured by DXA. Thus, bone
turnover is driven by the withdrawal of estrogen [27]. In
contrast, postmenopausal women are in the slow phase of bone
loss. Instead, they experience an age-related insufficient calci-
um absorption from the intestines, which causes an increase in
parathyroid hormone (PTH) with resorption of calcium from
the bones to maintain a systemic steady state of calcium in the
blood. Thus, PTH is the dominating mechanism associated to
bone turnover in postmenopausal women [27]. When post-
menopausal women receive calcium and vitamin D supple-
ments, bone turnover decreases due to closing of the gaps of
remodeling. This is seen as an increase in BMD [27].
At follow-up, the majority (72%) of patients had received a
daily calcium and vitamin D supplement during chemotherapy,
Fig. 2 Changes in median
BMD and interquartile ranges
for DXA scans before and after
chemotherapy in 97 Danish
patients with early-stage breast
cancer
Table 2 Absolute (ΔBMD) and relative (Coef.) changes in spine BMD from baseline to completion of adjuvant chemotherapy in 97 Danish patients
with early-stage breast cancer
Lumbar spine Univariate analyses Multivariate analysesc
Co-variates Number ΔBMDa (%) 95 % CI Coef.b (%) P value 95 % CI Coef.b (%) P value 95 % CI
Prednisolone pr. 1 g 97 0.97 −1.5;3.4 0.97 0.43 −1.5;3.4 1.57 0.17 −0.7;3.8
Premenopausal at diagnosis 43 0.03 −0.8;0.8 0 (ref.) 0 (ref.)
Postmenopausal at diagnosis 54 2.42 1.6;3.3 2.39 <0.001 1.2;3.6 2.35 <0.001 1.1;3.6
Never/former smoker 80 1.70 1.0;2.4 0 (ref.) 0 (ref.)
Current smoker 17 0.22 −1.5;1.1 −1.92 0.02 −3.6;−0.3 −1.67 0.04 −3.3;−0.1
BMI (<25) 38 1.03 0.1;1.9 0 (ref.) 0 (ref.)
BMI (25–30) 36 1.70 0.7;2.7 0.67 0.37 −0.8;2.1 0.19 0.78 −1.2;1.6
BMI (>30) 23 1.39 −0.3;3.1 0.36 0.67 −1.3;2.0 −0.40 0.61 −2.0;1.2
aΔBMD=mean percent change
bCoef. coefficient = (BMD at follow-up−BMD at baseline) / BMD at baseline × 100 %=mean percent change in BMD (%)
cMultivariate analyses adjusted for prednisolone, menopausal status, smoking, and BMI
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which most likely has contributed to the increased BMD ob-
served in our study. We examined whether there was a differ-
ence in BMD between patients who received calcium and vi-
tamin D supplements and those who did not and noted an
increase in spine and hip BMD in both the groups. However,
the analyses were based on too few patients to give a mean-
ingful result. The reduction in BMD observed in current
smokers fits well with the explanation since one of the delete-
rious effects of smoking on bone is to reduce intestinal calcium
absorption [28].
At baseline, 9 % of patients (10/111 patients) were diag-
nosed with osteoporosis. In 2010, the prevalence of osteopo-
rosis was estimated to be 21% inDanishwomen aged 50 years
or more and 5 % in the general population when measuring
hip BMD [5]. In another study of 9933 Danish women, the
prevalence of osteoporosis was reported to be 14 % when
BMD was measured at the spine, hip, or both [29]. Our
patients had mean baseline Z-scores greater than zero for all
the anatomic sites, which translates into higher BMD values at
baseline compared to the female background population of the
same age. However, the mean Z-scores may represent an over-
estimation of BMD, due to possible selection bias of the
patients included in the study.
The main strength of our study is the prospective data
collection. All eligible patients were enrolled consecutively
in the study and had a baseline DXA performed before onset
of the first cycle of chemotherapy. Each patient was her own
control, and the second DXA was performed on the same
DXA scanner approximately 3 weeks after completion of
chemotherapy. Only four patients started endocrine treatment
before the second DXAwas performed.
However, there are some limitations to our study, one of
them being that it is a single institution experience limiting the
generalizability. We had no reliable information on alcohol
consumption, physical activity, or prior hormone replacement
therapy which are known to affect bone density in a positive
way mostly among postmenopausal women [30–32]. We did
not check the compliance to prednisolone prescribed as an
anti-emetic treatment, and we were also unable to account
for glucocorticoids, prescribed for underlying medical indica-
tions. Also, it would have been preferable to include a control
group without steroids but it was considered unethical to with-
hold steroids as anti-emetic treatment from these patients.
Finally, unfortunately, we had no measurements of vitamin
D or biochemical markers of bone turnover.
Conclusion
In summary, contrary to expectation, we found that adjuvant
anthracycline- and taxane-based chemotherapy supplemented
with supportive therapy (prednisolone) for early-stage breast
cancer was not associated with bone loss when supplemented
with calcium and vitamin D. Postmenopausal women gained
significantly bone mass in the spine, whereas current smokers
had a significant bone loss in the spine. It was reassuring, that
no significant association was detected between prednisolone
dose and changes in BMD. Furthermore, guidelines have
changed, and lower total doses are now recommended as
anti-emetic prophylaxis allowing the use of corticosteroids
to continue in anti-emetic treatment. Our data suggest that in
patients who receive chemotherapy, it may not be necessary to
perform a DXA before start of chemotherapy, but that it will
be safe to postpone it until later.
Acknowledgments Funding for this study was provided by the Region
of Southern Denmark; the Department of Oncology, Odense University
Hospital; the Department of Endocrinology, Odense University Hospital;
the Danish Cancer Society; and the University of Southern Denmark.
A special thanks to all the patients who participated in the study and to
the doctors, nurses, and secretaries at the Department of Oncology,
Odense University Hospital, Denmark, for each of their contribution to
make this project possible.
Also a special thanks to the staff, and in particularly, to Jane Nielsen at
the Osteoporosis Clinic, Department of Endocrinology, Odense
University Hospital, Denmark.
Compliance with ethical standards
Conflict of interest The authors declare that they have no competing
interests.
Open Access This article is distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits any noncom-
mercial use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons license, and indicate if changes were
made.
References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S,Mathers C, RebeloM,
Parkin DM, Forman D, Bray F (2015) Cancer incidence and
mortality worldwide: sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer 136(5):E359–386. doi:10.1002/
ijc.29210
2. Howlader N NA, Krapcho M, Garshell J, Miller D, Altekruse
SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis
DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer
Statistics Review, 1975–2011, National Cancer Institute.
Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based
on November 2013 SEER data submission, posted to the
SEER web site, April 2014
3. Tryggvadottir L, Gislum M, Bray F, Klint A, Hakulinen T, Storm
HH, EngholmG (2010) Trends in the survival of patients diagnosed
with breast cancer in the Nordic countries 1964–2003 followed up
to the end of 2006. Acta Oncol 49(5):624–631. doi:10.3109/
02841860903575323
4. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann
B, Senn HJ, Panel M (2011) Strategies for subtypes—dealing
with the diversity of breast cancer: highlights of the St. Gallen
International Expert Consensus on the Primary Therapy of
Support Care Cancer (2016) 24:4229–4236 4235
Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi:
10.1093/annonc/mdr304
5. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C,
Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013)
Osteoporosis in the European Union: medical management, ep-
idemiology and economic burden. A report prepared in collab-
oration with the International Osteoporosis Foundation (IOF)
and the European Federation of Pharmaceutical Industry
Associations (EFPIA). Arch Osteoporos 8(1–2):136. doi:10.
1007/s11657-013-0136-1
6. ColemanRE, Rathbone E, Brown JE (2013)Management of cancer
treatment-induced bone loss. Nat Rev Rheumatol 9(6):365–374.
doi:10.1038/nrrheum.2013.36
7. Shapiro C, Manola J, Leboff M (2001) Ovarian failure after
adjuvant chemotherapy is associated with rapid bone loss in
women with early-stage breast cancer. J Clin Oncol 19(14):
3306–3311
8. Vehmanen L, Saarto T, Risteli J, Risteli L, Blomqvist C, Elomaa I
(2004) Short-term intermittent intravenous clodronate in the pre-
vention of bone loss related to chemotherapy-induced ovarian fail-
ure. Breast Cancer Res Treat 87(2):181–188. doi:10.1023/
B:BREA.0000041624.00665.4e
9. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D,
Cucchiara G, Brafman L, Shane E (2008) Zoledronic acid prevents
bone loss in premenopausal women undergoing adjuvant chemother-
apy for early-stage breast cancer. J Clin Oncol 26(29):4739–4745.
doi:10.1200/JCO.2008.16.4707
10. Cameron DA, Douglas S, Brown JE, Anderson RA (2010) Bone
mineral density loss during adjuvant chemotherapy in pre-
menopausal women with early breast cancer: is it dependent on
oestrogen deficiency? Breast Cancer Res Treat 123(3):805–814.
doi:10.1007/s10549-010-0899-7
11. Weinstein RS (2011) Clinical practice. Glucocorticoid-induced
bone disease. N Engl J Med 365(1):62–70. doi:10.1056/
NEJMcp1012926
12. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E,
Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P,
Cartei F, Nardi M, Pinchera A (2001) Comparison of the effec-
tiveness and tolerability of intravenous or oral glucocorticoids
associated with orbital radiotherapy in the management of
severe Graves’ ophthalmopathy: results of a prospective,
single-blind, randomized study. J Clin Endocrinol Metab
86(8):3562–3567. doi:10.1210/jcem.86.8.7737
13. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB,
Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on
proximal femur bone mineral levels of US adults. Osteoporos
Int 8(5):468–489
14. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well
measures of bone mineral density predict occurrence of osteoporot-
ic fractures. BMJ 312(7041):1254–1259
15. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998)
Inhibition of osteoblastogenesis and promotion of apoptosis of
osteoblasts and osteocytes by glucocorticoids. Potential mech-
anisms of their deleterious effects on bone. J Clin Invest 102(2):
274–282. doi:10.1172/JCI2799
16. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C
(2000) Use of oral corticosteroids and risk of fractures. J Bone
Miner Res 15(6):993–1000. doi:10.1359/jbmr.2000.15.6.993
17. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van
Staa TP (2007) Fracture risk with intermittent high-dose oral glu-
cocorticoid therapy. Arthritis Rheum 56(1):208–214. doi:10.1002/
art.22294
18. Herrstedt J, Rapoport B, Warr D, Roila F, Bria E, Rittenberg C,
Hesketh PJ (2011) Acute emesis: moderately emetogenic chemo-
therapy. Support Care Cancer 19(Suppl 1):S15–23. doi:10.1007/
s00520-010-0951-5
19. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C
(2003) Bone density threshold and other predictors of vertebral
fracture in patients receiving oral glucocorticoid therapy. Arthritis
Rheum 48(11):3224–3229. doi:10.1002/art.11283
20. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk
of vertebral fracture and relationship to bone mineral density in
steroid treated rheumatoid arthritis. Ann Rheum Dis 54(10):801–
806
21. Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment:
pathogenesis and management. J Clin Oncol 18(7):1570–1593
22. Wissing MD (2015) Chemotherapy- and irradiation-induced bone
loss in adults with solid tumors. Curr Osteoporos Rep 13(3):140–
145. doi:10.1007/s11914-015-0266-z
23. Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmanian FA
(1994) Calcium supplementation with and without hormone re-
placement therapy to prevent postmenopausal bone loss. Ann
Intern Med 120(2):97–103
24. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G,
Muchmore DB (2003) Effects of raloxifene, hormone replacement
therapy, and placebo on bone turnover in postmenopausal women.
Osteoporos Int 14(10):814–822. doi:10.1007/s00198-003-1434-z
25. Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the
construction and conservation of the adult skeleton. Endocr Rev
23(3):279–302. doi:10.1210/edrv.23.3.0465
26. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996)
Increased bone turnover in late postmenopausal women is a major
determinant of osteoporosis. J BoneMiner Res 11(3):337–349. doi:
10.1002/jbmr.5650110307
27. Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for
involutional osteoporosis: estrogen deficiency causes both type I
and type II osteoporosis in postmenopausal women and contributes
to bone loss in aging men. J Bone Miner Res 13(5):763–773. doi:
10.1359/jbmr.1998.13.5.763
28. Wong PK, Christie JJ, Wark JD (2007) The effects of smoking on
bone health. Clin Sci (Lond) 113(5):233–241. doi:10.1042/
CS20060173
29. Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is
markedly underdiagnosed: a nationwide study from Denmark.
Osteoporos Int 16(2):134–141. doi:10.1007/s00198-004-1680-8
30. Feskanich D, Korrick SA, Greenspan SL, Rosen HN, Colditz GA
(1999) Moderate alcohol consumption and bone density among
postmenopausal women. J Women’s Health 8(1):65–73
31. KarlssonM (2004) Has exercise an antifracture efficacy in women?
Scand J Med Sci Sports 14(1):2–15
32. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B,
Downey LJ (1995) Comparison of oral estrogens and estrogens plus
androgen on bone mineral density, menopausal symptoms, and
lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol
85(4):529–537
4236 Support Care Cancer (2016) 24:4229–4236
